Toralac (ketorolac tromethamine): Uses, Dosage & Side Effects

What it's for (Indications)

Ketorolac tromethamine is indicated for the short-term (up to 5 days total for all routes of administration combined) management of moderately severe acute pain that requires analgesia at the opioid level.
It is typically employed in situations where the severity of pain warrants potent relief, and non-opioid strategies are preferred or necessary to minimize opioid exposure, or as part of a multimodal analgesic regimen.
Common clinical scenarios include postoperative pain following surgical procedures, acute musculoskeletal injuries, and other acute pain conditions where the anti-inflammatory and analgesic properties are beneficial.
Its potent analgesic effect allows for its use in reducing opioid consumption and associated side effects.
Ketorolac can be administered via various routes, including intramuscular (IM) injection, intravenous (IV) injection, and orally, providing flexibility in clinical settings.
The acute nature of its indication is critical due to the significant risk of serious adverse events associated with prolonged use, thus restricting its application to severe acute pain where benefits outweigh the risks of short-term use.

Dosage Information

Type	Guideline
Standard	The dosage of ketorolac tromethamine must be carefully individualized based on the patient's condition, age, weight, and renal function, always adhering to the strict maximum duration of 5 days for all routes combined to mitigate severe adverse risks. For adult patients under 65 years of age, typical intramuscular or intravenous dosing begins with a 30 mg single dose or 30 mg every 6 hours, not exceeding a maximum daily dose of 120 mg. For oral administration, a 20 mg initial dose is often followed by 10 mg every 4 to 6 hours, with a maximum daily oral dose of 40 mg. In elderly patients (65 years and older), those with impaired renal function, or those weighing less than 50 kg, the dosage should be reduced, often to half the adult dose (e.g., 15 mg IM/IV every 6 hours, not exceeding 60 mg/day; 10 mg oral every 4-6 hours, maximum 40 mg/day). Transition from parenteral to oral administration should occur as soon as feasible, with the combined total daily dose from both routes not exceeding the recommended maximums and always within the 5-day cumulative limit. It is imperative to use the lowest effective dose for the shortest possible duration to minimize the risk of adverse effects.

Type

Guideline

Standard

The dosage of ketorolac tromethamine must be carefully individualized based on the patient's condition, age, weight, and renal function, always adhering to the strict maximum duration of 5 days for all routes combined to mitigate severe adverse risks. For adult patients under 65 years of age, typical intramuscular or intravenous dosing begins with a 30 mg single dose or 30 mg every 6 hours, not exceeding a maximum daily dose of 120 mg. For oral administration, a 20 mg initial dose is often followed by 10 mg every 4 to 6 hours, with a maximum daily oral dose of 40 mg. In elderly patients (65 years and older), those with impaired renal function, or those weighing less than 50 kg, the dosage should be reduced, often to half the adult dose (e.g., 15 mg IM/IV every 6 hours, not exceeding 60 mg/day; 10 mg oral every 4-6 hours, maximum 40 mg/day). Transition from parenteral to oral administration should occur as soon as feasible, with the combined total daily dose from both routes not exceeding the recommended maximums and always within the 5-day cumulative limit. It is imperative to use the lowest effective dose for the shortest possible duration to minimize the risk of adverse effects.

Safety & Warnings

Common Side Effects

Ketorolac tromethamine, due to its potent nonsteroidal anti-inflammatory drug (NSAID) activity, is associated with a wide range of potential side effects, some of which can be serious or life-threatening.
Common adverse reactions primarily involve the gastrointestinal system, manifesting as dyspepsia, nausea, abdominal pain, diarrhea, and constipation.
More severe gastrointestinal effects include gastritis, erosions, peptic ulceration, and potentially life-threatening gastrointestinal bleeding or perforation, particularly with prolonged use or in susceptible individuals.
Renal adverse effects can manifest as acute kidney injury, fluid retention, edema, hyperkalemia, and interstitial nephritis, especially in patients with pre-existing renal impairment, heart failure, or dehydration.
Cardiovascular risks include the development or exacerbation of hypertension, and an increased risk of serious thrombotic events such as myocardial infarction (MI) and stroke, which can be fatal.
Other reported side effects include headache, dizziness, somnolence, sweating, injection site pain (for parenteral administration), and hypersensitivity reactions such as rash, pruritus, and anaphylaxis.
Liver function abnormalities, tinnitus, and visual disturbances have also been noted.

Serious Warnings

Black Box Warning: WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Ketorolac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Ketorolac tromethamine carries several significant warnings, including a prominent Black Box Warning issued by regulatory authorities due to its potential for serious and life-threatening adverse events.
Foremost among these is the increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
This risk is dose-dependent and increases significantly with the duration of use.
Patients with a history of GI disease, concomitant use of anticoagulants, corticosteroids, or selective serotonin reuptake inhibitors (SSRIs), or advanced age are particularly vulnerable.
Secondly, there is an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction (MI) and stroke, which can be fatal.
This risk may increase with duration of use and in patients with cardiovascular disease or multiple risk factors.
Ketorolac is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Additionally, it can cause renal papillary necrosis and other renal injury, particularly in patients with pre-existing renal disease, heart failure, hypovolemia, or dehydration; it is contraindicated in patients with advanced renal impairment.
It should not be used for obstetric analgesia or pre-operatively because of its effect on platelet aggregation, which can increase the risk of bleeding.
The total duration of ketorolac treatment by all routes must not exceed 5 days due to the heightened risk of these serious adverse events with prolonged use.
Concomitant use with other NSAIDs or aspirin should be avoided due to additive gastrointestinal and bleeding risks.

How it Works (Mechanism of Action)

Ketorolac tromethamine exerts its therapeutic effects primarily through the reversible inhibition of cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. Cyclooxygenase enzymes are critical in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins from arachidonic acid, which are lipid mediators involved in various physiological and pathophysiological processes. By inhibiting COX-1, ketorolac reduces the production of prostaglandins that play protective roles in the gastric mucosa, are involved in renal blood flow regulation, and mediate platelet aggregation. This inhibition contributes to the analgesic and anti-inflammatory effects but also underlies many of its common and serious adverse effects, such as gastrointestinal irritation, bleeding, and renal dysfunction. The inhibition of COX-2 reduces the synthesis of prostaglandins primarily involved in mediating pain, inflammation, and fever at sites of tissue injury. The overall pharmacological outcome is potent analgesia, significant anti-inflammatory activity, and an antipyretic effect. Its mechanism of action categorizes it as a nonselective NSAID, meaning it inhibits both COX isoforms, distinguishing it from selective COX-2 inhibitors.